Observation on the Therapeutic Efficacy of Camrelizumab Combined with Chemotherapy in Non-small Cell Lung Cancer and the Cutaneous Immune-related Adverse Events: A Retrospective Study
The presence of cirAEs in NSCLC patients treated with camrelizumab combined with chemotherapy is indicative of better treatment efficacy and prognosis. This study supports the utility of cirAEs as biomarkers for predicting the validity of immunotherapy in NSCLC. It proposes a novel, multi-parameter prognostic model to assess patient outcomes more accurately.
Authors
- Aoyang Yü (ORCID: https://orcid.org/0009-0006-0214-4771)
- Jiali Xia (ORCID: https://orcid.org/0009-0008-9755-0186)
- Xiaobing Qin (ORCID: https://orcid.org/0000-0002-0910-4565)
- Wenlou Liu
- Menghan Cao
- Zhengxiang Han (ORCID: https://orcid.org/0000-0003-2463-8933)
- Zhao Yang (ORCID: https://orcid.org/0000-0002-9143-671X)
- Guan Jiang
- Hongmei Wang
Institutions
- Xuzhou Medical College (CN)
Publication Details
- Journal
- Anti-Cancer Agents in Medicinal Chemistry
- Published
- 2025-01-09
- DOI
- https://doi.org/10.2174/0118715206350978241105080452
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09